Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186628 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
A Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00186628 is a Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell that has completed, run by Stanford University. The registered enrollment target is 36 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00186628, a Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Cyclosporine
- DRUG Mycophenylate mofetil
- PROCEDURE Total lymphoid irradiation
- DRUG Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186628
The ClinicalTrials.gov registry entry for NCT00186628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (65% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Rituximab is the first listed.
NCT00186628 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00186628 about?
NCT00186628 is a clinical study titled "Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD". To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
What is the current status of trial NCT00186628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-06. Estimated completion is 2010-12.
What conditions does trial NCT00186628 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Leukemia, Mast-Cell.
What interventions are being tested in trial NCT00186628?
The interventions under investigation include: Rituximab (DRUG), Cyclosporine (DRUG), Mycophenylate mofetil (DRUG), Total lymphoid irradiation (PROCEDURE), Anti-thymoglobulin, rabbit (ATG, rabbit ATG) (DRUG).
Who is sponsoring clinical trial NCT00186628?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186628 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RECRUITING · Phase 2
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.